Zurich Cantonal Bank
VRDN icon

Zurich Cantonal Bank’s Viridian Therapeutics VRDN Stock Holding History

Zurich Cantonal Bank’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$841K Buy
45,760
+8,298
+22% +$134K ﹤0.01% 1653
2026
Q1 		$733K Buy
37,462
+14,112
+60% +$419K ﹤0.01% 1609
2025
Q4 		$727K Sell
23,350
-3,618
-13% -$99.2K ﹤0.01% 1546
2025
Q3 		$582K Hold
26,968
– – ﹤0.01% 1651
2025
Q2 		$377K Buy
26,968
+8,304
+44% +$113K ﹤0.01% 1834
2025
Q1 		$252K Hold
18,664
– – ﹤0.01% 1973
2024
Q4 		$358K Buy
18,664
+4,667
+33% +$101K ﹤0.01% 1830
2024
Q3 		$318K Buy
13,997
+2,036
+17% +$33.3K ﹤0.01% 1842
2024
Q2 		$156K Buy
11,961
+2,359
+25% +$32.7K ﹤0.01% 2160
2024
Q1 		$168K Buy
9,602
+1,233
+15% +$23.9K ﹤0.01% 2140
2023
Q4 		$182K Buy
8,369
+4,610
+123% +$72.8K ﹤0.01% 2137
2023
Q3 		$57.7K Hold
3,759
– – ﹤0.01% 2565
2023
Q2 		$89.4K Hold
3,759
– – ﹤0.01% 2396
2023
Q1 		$95.6K Hold
3,759
– – ﹤0.01% 2301
2022
Q4 		$110K Hold
3,759
– – ﹤0.01% 2211
2022
Q3 		$77K Buy
+3,759
New +$67.6K ﹤0.01% 2403

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Zurich Cantonal Bank's VRDN Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Viridian Therapeutics (VRDN) stake by 22% in Q2 2026, buying an estimated $134K and bringing the position to 45,760 shares worth $841K. The position accounts for ﹤0.01% of the portfolio, ranked #1653.

Zurich Cantonal Bank first reported a position in VRDN in Q3 2022 and has held it in 16 quarters since. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Zurich Cantonal Bank held 45,760 shares of Viridian Therapeutics worth $841K as of Q2 2026.
  • Zurich Cantonal Bank bought 8,298 Viridian Therapeutics shares in Q2 2026, an estimated $134K.
  • Viridian Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1653 holding.
  • Zurich Cantonal Bank first reported a position in Viridian Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.